Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario.

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Casadei-Gardini, Andrea
;
Della Corte, Angelo;Ratti, Francesca;De Cobelli, Francesco;Aldrighetti, Luca;Cascinu, Stefano;
2022-01-01

Abstract

Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario.
2022
Advanced HCC
Atezolizumab
Bevacizumab
Lenvatinib
NAFLD
NASH
RWD
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/134752
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 36
social impact